| Size | Price | Stock | Qty |
|---|---|---|---|
| 50g |
|
||
| 100g |
|
||
| Other Sizes |
| Targets |
5-Hexen-1-ol is a synthetic intermediate and does not have a defined biological drug target. As a simple unsaturated alcohol, it is not designed to bind to specific proteins, enzymes, or receptors within biological systems. Instead, its chemical reactivity enables it to act as a precursor for the synthesis of more complex pharmaceutical compounds. Therefore, in the context of drug development, its role is to provide a versatile chemical platform for constructing molecules that possess targeted biological activities. It has no reported affinity for therapeutic targets such as kinases, GPCRs, or ion channels.
|
|---|---|
| ln Vitro |
5-Hexen-1-ol is a biochemical reagent that can be utilized in life science research as an organic compound or biological material.
No validated in vitro biological activity data are available for 5-Hexen-1-ol, as it is primarily utilized as a chemical synthetic intermediate rather than a pharmacologically active agent. It has not been shown to induce specific cellular responses such as cytotoxicity, apoptosis, or signal transduction modulation in cultured cells. In biochemical experiments, it serves as a starting material for the synthesis of molecules with potential antimicrobial or other bioactive properties, but the parent compound itself does not exhibit measurable activity in standard cell-based assays. Any observed effects in vitro would be attributable to its downstream synthetic derivatives rather than the compound itself. |
| ln Vivo |
No in vivo pharmacological activity data are available for 5-Hexen-1-ol. The compound has not been evaluated in animal models for efficacy in treating any disease condition, as its function is predominantly as a synthetic precursor rather than an active pharmaceutical ingredient. It may be used as a reagent in ex vivo chemical synthesis studies, but no pharmacokinetic or pharmacodynamic studies have been reported for this compound in living organisms. Therefore, it should not be considered a candidate for in vivo therapeutic applications.
|
| Enzyme Assay |
As a simple chemical alcohol, 5-Hexen-1-ol is not used in enzyme or receptor binding assays. There are no reported studies investigating its direct interaction with any purified enzyme or receptor protein. In contrast to chromogenic or radiolabeled substrates, 5-Hexen-1-ol lacks the structural features required to serve as a high-affinity ligand for biological macromolecules. Consequently, standard enzyme inhibition or receptor binding protocols are not applicable to this compound, and no experimental procedures have been established or published for such purposes.
|
| Cell Assay |
No standardized cell-based experimental protocols exist specifically for 5-Hexen-1-ol, as it is not a bioactive molecule intended for cellular assays. However, for general handling in research settings, the compound is typically dissolved in organic solvents such as ethanol or DMSO to prepare stock solutions. It can be added to cell culture media at low concentrations (<0.1% v/v) for evaluating its compatibility with biological systems, though no specific cell lines or assay readouts are recommended. For cytotoxicity screening, a typical protocol would involve seeding cells in 96-well plates, treating with serial dilutions of the compound (1-1000 microM), and measuring viability using MTT or CellTiter-Glo after 24-72 hours of incubation.
|
| Animal Protocol |
No in vivo animal experiments have been conducted or reported for 5-Hexen-1-ol as a test article. The compound is not intended for therapeutic use, and therefore no efficacy studies in disease models or safety pharmacology assessments have been performed. In the context of chemical synthesis research, it may be used as a starting material to generate compounds for subsequent animal studies, but the parent compound itself is not administered to animals for pharmacological evaluation. Standard practices for handling organic solvents in laboratory animals would apply if any incidental administration were to occur, but such data are not available.
|
| ADME/Pharmacokinetics |
No pharmacokinetic data are available for 5-Hexen-1-ol. As a small, lipophilic alcohol (molecular weight 100.16 g/mol), it is expected to be rapidly absorbed if administered, but no absorption, distribution, metabolism, excretion (ADME), or bioavailability studies have been reported. It is not a drug candidate, and comprehensive PK profiling has not been performed. The compound is stable under standard storage conditions but should be kept away from strong oxidizing agents. Solubility is moderate in water and good in most organic solvents (ethanol, ether).
|
| Toxicity/Toxicokinetics |
5-Hexen-1-ol is classified as an irritant and can cause skin and eye irritation upon direct contact. Inhalation of vapors may cause respiratory tract irritation. The compound has low acute toxicity (oral LD50 >2000 mg/kg in rats, estimated based on structurally similar alcohols). Chronic exposure data are not available. Standard laboratory precautions (gloves, goggles, fume hood) should be used. It is not classified as a carcinogen, mutagen, or reproductive toxin under GHS regulations.
|
| Additional Infomation |
According to reports, thyme contains 5-hexen-1-ol, and relevant data is available for reference.
5-Hexen-1-ol is not a drug and has not undergone clinical trials nor received regulatory approval for therapeutic use. It is exclusively distributed as a research-grade chemical reagent for synthetic chemistry and biochemical experimentation. The compound is recognized in flavor and fragrance formulations as a safe additive (generally recognized as safe, GRAS, by FEMA, flavor number 4401) but not for pharmaceutical administration. In drug development, it serves as an intermediate for synthesizing more complex molecules, such as tetrahydropyran derivatives, which may then be evaluated as drug candidates. No patent data or specific therapeutic applications are associated with the compound itself. |
| Molecular Formula |
C6H12O
|
|---|---|
| Molecular Weight |
100.16
|
| Exact Mass |
100.088
|
| CAS # |
821-41-0
|
| PubChem CID |
69963
|
| Appearance |
Colorless to light yellow liquid（Density：0.8453 g/cm³）
|
| Density |
0.8±0.1 g/cm3
|
| Boiling Point |
149.9±19.0 °C at 760 mmHg
|
| Melting Point |
<-20ºC
|
| Flash Point |
47.2±0.0 °C
|
| Vapour Pressure |
1.5±0.6 mmHg at 25°C
|
| Index of Refraction |
1.431
|
| LogP |
1.5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
7
|
| Complexity |
41.4
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OCCCCC=C
|
| InChi Key |
UIZVMOZAXAMASY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H12O/c1-2-3-4-5-6-7/h2,7H,1,3-6H2
|
| Chemical Name |
hex-5-en-1-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (998.40 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (24.96 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (24.96 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (24.96 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 9.9840 mL | 49.9201 mL | 99.8403 mL | |
| 5 mM | 1.9968 mL | 9.9840 mL | 19.9681 mL | |
| 10 mM | 0.9984 mL | 4.9920 mL | 9.9840 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
